RESUMEN
Objective: To assess Quality of life (QoL) and its associated factors in people living with HIV/AIDS (PLWHA) who taking highly active antiretroviral therapy (HAART) in Wangaya Hospital in Denpasar, Bali, Indonesia. Methods: A cross-sectional study was conducted during February 2019 to January 2020 at Wangaya Hospital in Denpasar, Bali, Indonesia. QoL was assessed using the five-level version of the EuroQol five-dimensional questionnaire (EQ-5D-5L), EQ-5D index value, and the EuroQol visual analogue scale (EQ-VAS). The data was analyzed using Statistical Package for Social Science (SPSS) software package version 26.0. Bivariate analysis was tested using the cross-tabulation Gamma, Kruskal-Wallis and post hoc Mann-Whitney test. P value<0.05 was considered as statistically significant. Results: A total of 584 PLWHA took HAART for at least 3 mo. The median index value and EQ-VAS were 1.0 (range-0.514–1.0) and 100.00 (range 30-100), respectively. Most patients had problems in ‘anxiety/depression’ and ‘pain/discomfort’ domains. Predictors of better QoL included men, married, good adherence, and treatment duration>24 mo (p<0.05). Predictor of poorer QoL included an advanced HIV clinical stage(p=0.001). Conclusion: The QoL scores of PLWHA receiving HAART in our study were high; hence the QoL of PLWHA was good. The good QoL can be taken as the goal for HIV treatment in order to have a successful HAART therapy.
RESUMEN
Objective: To estimate the Pulmonary Tuberculosis (PTB) prevalence among the participants/People Living With HIV/AIDS (PLWHAs) and to verify the association between WHO clinical staging and other risk factors with PTB. Methods: A cross-sectional study was conducted to estimate the PTB prevalence. Probable associated risk factors in PLWHAs with and without PTB were compared. The association between WHO clinical staging and other risk factors with PTB was investigated using bivariate analysis. A p-value<0.05 was considered statistically significant. Results: This study was conducted from January 2018 to December 2019, recruited about 584 participants with presumptive PTB and 20.72% (121) confirmed with PTB. In the bivariate analysis; participants who are on human immunodeficiency virus (HIV) Stage 4 (WHO clinical staging) were significantly more likely to develop PTB (p=0.000). PTB was significantly higher among male than female (p=0.000), higher among the older (p=0.030). PTB was significantly more frequent among participants with lower cluster differentiation 4 (CD4) cell counts (p=0.042). A contact history with a Tuberculosis (TB) patient was an important risk factor (p=0.000). PTB was significantly associated with smoking history (p=0.000). Conclusion: A high PTB prevalence was observed. There was a significantly association between the severity of WHO clinical staging, sex, age, lower CD4 cell count, a contact history with a tuberculosis (TB) patient and smoking history with PTB among PLWHAs.
RESUMEN
Aims: Particulate methane monooxygenase (pMMO) is an integral membrane protein that converts methane to methanol as the first step in the metabolic pathway of methanotroph bacteria. Methanotroph have a slow growth rate that make researcher have to develop an alternative approach by expressing the pMMO genes in Escherichia coli. However, it was very difficult to express all the pMMO encoded genes in E. coli and it is suspected that the protein might be toxic to E. coli. Therefore, this research tried another approach by expressing the active site of pMMO enzyme; cupredoxin domain of pmoB subunit encoded by spmoB gene. Methodology and results: The spmoB gene from Methylococcus capsulatus (Bath) was expressed in E. coli BL21 (DE3) under T7 promoter and pET15b as the expression vector. Several modifications were made so this gene would be expressed in the cytoplasm. Expression analysis with SDS-PAGE showed that overexpression of this gene could be done at several concentrations of IPTG and incubation temperature. The spmoB gene expression produced a recombinant protein with a size approximately 38.9 kDa. Assay of spmoB protein activity showed that the amount of methanol accumulated during methane oxidation by the recombinant strain was 0.114 mmol/mL culture.h. Conclusion, significance and impact study: We successfully expressed spmoB gene in E. coli BL21 (DE3) without high production of toxic compounds and it has methane oxidation activity. This result allowed further characterization of its potential applications.